NCT00382174View on ClinicalTrials.gov

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Pressure Ulcers
Interventions
DRUG

Placebo

Topical administration of 0.00% thymosin beta 4 qd up to 84 days

DRUG

Thymosin Beta 4

Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days

Trial Locations (12)

10032

New York Presbyterian Hospital, New York

16365

New Bridge Medical Center, Warren

23249

Mcguire VA Medical Center, Richmond

27599

University of North Carolina Hospital, Chapel Hill

32757

Mount Dora Research Center, Inc., Mt. Dora

33115

A+ Research, Inc., Miami

33744

Bay Pines VA Medical Center, Bay Pines

36111

Institute for Advanced Wound Care, Montgomery

60141

Hines VAMC, Hines

90211

Impact Clinical Trials, Beverly Hills

90822

Long Beach VAMC, Long Beach

01655

Wound Healing Laboratory Plastic Surgery UMass Medical Center, Worcester

All Listed Sponsors
lead

RegeneRx Biopharmaceuticals, Inc.

INDUSTRY

NCT00382174 - Study of Thymosin Beta 4 in Patients With Pressure Ulcers | Biotech Hunter | Biotech Hunter